For: | Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009; 15(7): 860-864 [PMID: 19230048 DOI: 10.3748/wjg.15.860] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v15/i7/860.htm |
Number | Citing Articles |
1 |
Jing Liu, Chao-Ran Ji, Yue-Yue Li, Chen Qiao, Jun-Nan Hu, Meng Wan, Min-Juan Lin, Bo-Shen Lin, Juan Wang, Jing Zha, Li-Xiang Li, Xiu-Li Zuo. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clinical and Translational Gastroenterology 2021; 12(8): e00391 doi: 10.14309/ctg.0000000000000391
|
2 |
Muhammad Miftahussurur, Modesto Cruz, Dalla Doohan, Phawinee Subsomwong, José A. Jiménez Abreu, Celso Hosking, Langgeng Agung Waskito, Yoshio Yamaoka, Iddya Karunasagar. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PLOS ONE 2019; 14(3): e0213868 doi: 10.1371/journal.pone.0213868
|
3 |
Francesco Costa, Mario M D’Elios. Management ofHelicobacter pyloriinfection. Expert Review of Anti-infective Therapy 2010; 8(8): 887 doi: 10.1586/eri.10.75
|
4 |
Dan Zhou, Xi Zhu, Yang Wang, Yun Jin, Xuefan Xu, Tingting Fan, Yan Liu, Zhirong Zhang, Yuan Huang. Preparation and characterization of a novel pH-sensitive coated microsphere for duodenum-specific drug delivery. Archives of Pharmacal Research 2012; 35(5): 839 doi: 10.1007/s12272-012-0509-9
|
5 |
Yong Xie, Zhenyu Zhang, Junbo Hong, Wenzhong Liu, Hong Lu, Yiqi Du, Weihong Wang, Jianming Xu, Xuehong Wang, Lijuan Huo, Guiying Zhang, Chunhui Lan, Xiaoyan Li, Yanqing Li, Hong Wang, Guoxin Zhang, Yin Zhu, Xu Shu, Ye Chen, Jiangbin Wang, Nonghua Lu. Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China. Helicobacter 2018; 23(5) doi: 10.1111/hel.12496
|
6 |
Shan Xu, Xiaohong Wu, Enguo Chen, Kejing Ying. Anti‐Helicobacter pylori Infection Treatment and Pulmonary Hypersensitivity: Case Series and Review of the Literature. The Clinical Respiratory Journal 2024; 18(8) doi: 10.1111/crj.13816
|
7 |
Anthony O'Connor, Javier Gisbert, Colm O’Morain. Treatment of Helicobacter pylori Infection. Helicobacter 2009; 14(s1): 46 doi: 10.1111/j.1523-5378.2009.00704.x
|
8 |
Frank J Senatore, Jonathan Wilmot, John W Birk. Helicobacter pyloritreatment: Still a work in progress. Postgraduate Medicine 2016; 128(1): 152 doi: 10.1080/00325481.2016.1103194
|
9 |
Dmitry S. Bordin, Irina N. Voynovan, Aiman S. Sarsenbaeva, Oleg V. Zaytsev, Rustam A. Abdulkhakov, Natalia V. Bakulina, Igor G. Bakulin, Marina F. Osipenko, Maria A. Livzan, Sergei A. Alekseenko. Effectiveness of empirical <i>Helicobacter pylori</i> eradication therapy with furazolidone in Russia: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). Terapevticheskii arkhiv 2023; 95(2): 120 doi: 10.26442/00403660.2023.02.202107
|
10 |
Ying Ying Han, Ji Yan Li, Jia Lun Guan, Mei Liu, Pei Yuan Li. Application of furazolidone in Helicobacter pylori infection eradication. Journal of Digestive Diseases 2024; 25(3): 148 doi: 10.1111/1751-2980.13265
|
11 |
Yingchao Sun, Mengjia Zhu, Lei Yue, Weiling Hu. Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy. Journal of Clinical Medicine 2022; 11(23): 7040 doi: 10.3390/jcm11237040
|
12 |
Airu Liu, Yuxin Wang, Yingxiao Song, Yiqi Du. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi Journal of Gastroenterology 2020; 26(2): 78 doi: 10.4103/sjg.SJG_589_19
|
13 |
Yong Xie, Yin Zhu, Hong Zhou, Zhi-Fa Lu, Zhen Yang, Xu Shu, Xiao-Bai Guo, Hui-Zhen Fan, Jian-Hua Tang, Xue-Ping Zeng, Jian-Bo Wen, Xiao-Qing Li, Xing-Xing He, Jiu-Hong Ma, Dong-Sheng Liu, Cai-Bin Huang, Ning-Jian Xu, Nong-Rong Wang, Nong-Hua Lu. Furazolidone-based triple and quadruple eradication therapy for <italic>Helicobacter pylori</italic> infection. World Journal of Gastroenterology 2014; 20(32): 11415-11421 doi: 10.3748/wjg.v20.i32.11415
|
14 |
David Y. Graham, Maria Pina Dore, Hong Lu. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Review of Anti-infective Therapy 2018; 16(9): 679 doi: 10.1080/14787210.2018.1511427
|
15 |
Kláudia Maria Machado Neves Silva, Diogo Émerson Leite de Carvalho, Vânia Maria Moreira Valente, Juan Carlos Campos Rubio, Paulo Eustáquio Faria, Priscila Pereira Silva-Caldeira. Concomitant and controlled release of furazolidone and bismuth(III) incorporated in a cross-linked sodium alginate-carboxymethyl cellulose hydrogel. International Journal of Biological Macromolecules 2019; 126: 359 doi: 10.1016/j.ijbiomac.2018.12.136
|
16 |
Chao-ran Ji, Jing Liu, Yue-yue Li, Chuan-guo Guo, Jun-yan Qu, Yan Zhang, Xiuli Zuo. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020; 10(10): e037375 doi: 10.1136/bmjopen-2020-037375
|
17 |
Hafez Fakheri, Zohreh Bari, Hossein Sardarian. A modified Bismuth‐Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure. Helicobacter 2012; 17(4): 264 doi: 10.1111/j.1523-5378.2012.00946.x
|
18 |
Xiao Liang, Xiaoqing Xu, Qing Zheng, Wei Zhang, Qinjuan Sun, Wenzhong Liu, Shudong Xiao, Hong Lu. Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study. Clinical Gastroenterology and Hepatology 2013; 11(7): 802 doi: 10.1016/j.cgh.2013.01.008
|
19 |
Yuemiao Zhang, Wen Gao, Hong Cheng, Xuezhi Zhang, Fulian Hu. Tetracycline‐ and Furazolidone‐containing Quadruple Regimen as Rescue Treatment for Helicobacter pylori Infection: A Single Center Retrospective Study. Helicobacter 2014; 19(5): 382 doi: 10.1111/hel.12143
|
20 |
Morris O. Makobongo, Tchelet Kovachi, Hanan Gancz, Amram Mor, D. Scott Merrell. In Vitro Antibacterial Activity of Acyl-Lysyl Oligomers againstHelicobacter pylori. Antimicrobial Agents and Chemotherapy 2009; 53(10): 4231 doi: 10.1128/AAC.00510-09
|
21 |
Tiankuo Yang, Renwei Hu, Xiaoqiong Tang, Yalin Shen, Alfred Tay, Xuenan Pi, Gang Wang, Aleksandra W Debowski, Keith A Stubbs, Mohammed Benghezal, Barry J Marshall, Hong Li, Hong Tang. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020; 3(2): 127 doi: 10.1093/pcmedi/pbaa010
|
22 |
Hafez Fakheri, Tarang Taghvaei, Vahid Hosseini, Zohreh Bari. A Comparison between Sequential Therapy and a Modified Bismuth‐based Quadruple Therapy for Helicobacter pylori Eradication in Iran: A Randomized Clinical Trial. Helicobacter 2012; 17(1): 43 doi: 10.1111/j.1523-5378.2011.00896.x
|
23 |
Hong Lu, Wei Zhang, David Y. Graham. Bismuth-containing quadruple therapy for Helicobacter pylori. European Journal of Gastroenterology & Hepatology 2013; : 1 doi: 10.1097/MEG.0b013e3283633b57
|
24 |
Liya Zhuge, Youhua Wang, Shuang Wu, Ru‐Lin Zhao, Zhen Li, Yong Xie. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta‐analysis. Helicobacter 2018; 23(2) doi: 10.1111/hel.12468
|
25 |
Elena Resina, Javier P. Gisbert. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics 2021; 10(9): 1028 doi: 10.3390/antibiotics10091028
|
26 |
Ya-Wen Zhang, Wei-Ling Hu, Yuan Cai, Wen-Fang Zheng, Qin Du, John J Kim, John Y Kao, Ning Dai, Jian-Min Si. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for <i>Helicobacter pylori</i> infection and predictors of failed eradication. World Journal of Gastroenterology 2018; 24(40): 4596-4605 doi: 10.3748/wjg.v24.i40.4596
|
27 |
Anthony O’Connor, Javier P. Gisbert, Deirdre McNamara, Colm O’Morain. Treatment of Helicobacter pylori Infection 2010. Helicobacter 2010; 15(s1): 46 doi: 10.1111/j.1523-5378.2010.00774.x
|
28 |
Nicolás Zuluaga Arbelaez, Elsy Cristina Sierra-Vargas, Luis Gonzalo Guevara-Casallas, Santiago Pérez-Viana. Estrategias terapéuticas para Helicobacter pylori en Colombia. CES Medicina 2021; 35(3): 244 doi: 10.21615/cesmedicina.6224
|
29 |
Hanxin Bi, Xingxing Chen, Yuxin Chen, Xin Zhao, Shasha Wang, Jiehong Wang, Ting Lyu, Shuang Han, Tao Lin, Mingquan Li, Donghong Yuan, Junye Liu, Yongquan Shi. Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. Chinese Medical Journal 2022; 135(14): 1707 doi: 10.1097/CM9.0000000000002289
|
30 |
Jiali Zhang, Chunling Rong, Chenyang Yan, Jie Chen, Wenjun Yang, Lingyan Yu, Haibin Dai, Muhammad Shahzad Aslam. Risk factors of furazolidone-associated fever. PLOS ONE 2022; 17(4): e0266763 doi: 10.1371/journal.pone.0266763
|
31 |
Francisco Buitrago Ramírez, Eloísa Rodríguez Torres, Javier Alejandre Carmona. Criterios actuales para la erradicación de Helicobacter pylori. FMC - Formación Médica Continuada en Atención Primaria 2010; 17(3): 158 doi: 10.1016/S1134-2072(10)70063-3
|
32 |
Saghi Riahizadeh, Reza Malekzadeh, Shahram Agah, Nasrin Zendehdel, Rasoul Sotoudehmanesh, Naser Ebrahimi‐Dariani, Akram Pourshams, Homayoon Vahedi, Javad Mikaeli, Morteza Khatibian, Sadegh Massarrat. Sequential Metronidazole‐Furazolidone or Clarithromycin‐Furazolidone Compared to Clarithromycin‐Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double‐Blind Randomized Controlled Trial. Helicobacter 2010; 15(6): 497 doi: 10.1111/j.1523-5378.2010.00798.x
|
33 |
Yang Yang, Ruizhuo Ouyang, Lina Xu, Ning Guo, Weiwei Li, Kai Feng, Lei Ouyang, Zhuoyuan Yang, Shuang Zhou, Yuqing Miao. Review: Bismuth complexes: synthesis and applications in biomedicine. Journal of Coordination Chemistry 2015; 68(3): 379 doi: 10.1080/00958972.2014.999672
|